Bacteria generally live in species-rich communities, such as the gut microbiota. Yet little is known about bacterial evolution in natural ecosystems. Here, we followed the long-term evolution of commensal Escherichia coli in the mouse gut. We observe the emergence of mutation rate polymorphism, ranging from wild-type levels to 1,000-fold higher. By combining experiments, whole-genome sequencing, and in silico simulations, we identify the molecular causes and explore the evolutionary conditions allowing these hypermutators to emerge and coexist within the microbiota. The hypermutator phenotype is caused by mutations in DNA polymerase III proofreading and catalytic subunits, which increase mutation rate by approximately 1,000-fold and stabilise hypermutator fitness, respectively. Strong mutation rate variation persists for >1,000 generations, with coexistence between lineages carrying 4 to >600 mutations. The in vivo molecular evolution pattern is consistent with fitness effects of deleterious mutations sd ≤ 10-4/generation, assuming a constant effect or exponentially distributed effects with a constant mean. Such effects are lower than typical in vitro estimates, leading to a low mutational load, an inference that is observed in in vivo and in vitro competitions. Despite large numbers of deleterious mutations, we identify multiple beneficial mutations that do not reach fixation over long periods of time. This indicates that the dynamics of beneficial mutations are not shaped by constant positive Darwinian selection but could be explained by other evolutionary mechanisms that maintain genetic diversity. Thus, microbial evolution in the gut is likely characterised by partial sweeps of beneficial mutations combined with hitchhiking of slightly deleterious mutations, which take a long time to be purged because they impose a low mutational load. The combination of these two processes could allow for the long-term maintenance of intraspecies genetic diversity, including mutation rate polymorphism. These results are consistent with the pattern of genetic polymorphism that is emerging from metagenomics studies of the human gut microbiota, suggesting that we have identified key evolutionary processes shaping the genetic composition of this community.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064181 | PMC |
http://dx.doi.org/10.1371/journal.pbio.3000617 | DOI Listing |
Cancer Manag Res
March 2025
Department of internal medicine, King Hussein Cancer Center, Amman, Jordan.
Background And Aim: Ovarian metastasis occurs in 3-5% of patients with CRC. Ovaries are considered sanctuary sites and typically do not respond effectively to chemotherapy. Patients with KRAS mutation generally have a worse prognosis compared to those with KRAS wild type.
View Article and Find Full Text PDFHeliyon
February 2025
Genetics and Molecular Biology branch, Department of Zoology, University of Dhaka, Dhaka, 1000, Bangladesh.
Budding yeast, is an ideal model organism for genetic research due to its similarity in life cycle and cellular structure to higher eukaryotes as well as its ease of cultivation and manipulation in the laboratory. Yeast cells benefit from being cultured in calorie-restricted media, which can be achieved by reducing glucose concentration from 2 % to 0.5 %.
View Article and Find Full Text PDFOncol Lett
April 2025
Division of Thoracic Medicine, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan 33305, Taiwan, R.O.C.
Currently, the clinical outcomes of patients with epidermal growth factor receptor ()-mutated non-small cell lung cancer (NSCLC) with baseline brain metastasis receiving first- and second-generation EGFR-tyrosine kinase inhibitors (TKIs) are not clear. The present study aimed to assess the clinical outcomes of patients with EGFR-mutated NSCLC with baseline brain metastasis who received first-line first- and second-generation EGFR-TKIs. In the present study, a retrospective analysis of clinical charts was performed to investigate first- and second-generation EGFR-TKIs in patients with -mutated NSCLC with baseline brain metastasis.
View Article and Find Full Text PDFFront Pharmacol
February 2025
Department of General Internal Medicine, Tianjin Hospital, Tianjin, China.
Background: is expressed in various tumors and leukemia cell lines. This study aims to explore the effect of in lung adenocarcinoma (LUAD).
Methods: The data on LUAD patients were collected from the Cancer Genome Atlas and Gene Expression Omnibus database.
Eur J Med Res
March 2025
Department of Gastroenterology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Background: This study sought to establish a risk score signature based on disulfidptosis-related genes (DRGs) to predict the prognosis of hepatocellular carcinoma (HCC) patients.
Methods: The expression data of DRGs from the Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC) was analyzed to develop and validate a DRG prognostic signature (DRGPS). In vitro, experiments were conducted to explore DRG expressions and roles in HCC tissues and cell lines.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!